[go: up one dir, main page]

ATE512661T1 - Verwendung eines betablockers zur herstellung eines arzneimittels zur behandlung von hämangiomen - Google Patents

Verwendung eines betablockers zur herstellung eines arzneimittels zur behandlung von hämangiomen

Info

Publication number
ATE512661T1
ATE512661T1 AT08838691T AT08838691T ATE512661T1 AT E512661 T1 ATE512661 T1 AT E512661T1 AT 08838691 T AT08838691 T AT 08838691T AT 08838691 T AT08838691 T AT 08838691T AT E512661 T1 ATE512661 T1 AT E512661T1
Authority
AT
Austria
Prior art keywords
hemangiomas
treatment
production
medicinal product
beta blocker
Prior art date
Application number
AT08838691T
Other languages
English (en)
Inventor
Christine Leaute-Labroze
De La Roque Eric Dumas
Alain Taieb
Jean-Benoit Thambo
Original Assignee
Univ Victor Segalen Bordeaux 2
Ct Hospitalier Universitaire De Bordeaux
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39156667&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE512661(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Univ Victor Segalen Bordeaux 2, Ct Hospitalier Universitaire De Bordeaux filed Critical Univ Victor Segalen Bordeaux 2
Application granted granted Critical
Publication of ATE512661T1 publication Critical patent/ATE512661T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/222—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin with compounds having aromatic groups, e.g. dipivefrine, ibopamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
    • A61K31/36—Compounds containing methylenedioxyphenyl groups, e.g. sesamin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4704—2-Quinolinones, e.g. carbostyril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Emergency Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Dermatology (AREA)
  • Vascular Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Otolaryngology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
AT08838691T 2007-10-19 2008-10-16 Verwendung eines betablockers zur herstellung eines arzneimittels zur behandlung von hämangiomen ATE512661T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP07291273A EP2050441A1 (de) 2007-10-19 2007-10-19 Verwendung von Beta-Blockern für die Herstellung eines Medikaments zur Behandlung von Hämangiomen
US98950707P 2007-11-21 2007-11-21
PCT/IB2008/002746 WO2009050567A2 (en) 2007-10-19 2008-10-16 Use of a beta blocker for the manufacture of a medicament for the treatment of hemangiomas

Publications (1)

Publication Number Publication Date
ATE512661T1 true ATE512661T1 (de) 2011-07-15

Family

ID=39156667

Family Applications (1)

Application Number Title Priority Date Filing Date
AT08838691T ATE512661T1 (de) 2007-10-19 2008-10-16 Verwendung eines betablockers zur herstellung eines arzneimittels zur behandlung von hämangiomen

Country Status (31)

Country Link
US (2) US8338489B2 (de)
EP (3) EP2050441A1 (de)
JP (1) JP5552700B2 (de)
KR (2) KR20150110827A (de)
CN (2) CN103169971A (de)
AR (1) AR068927A1 (de)
AT (1) ATE512661T1 (de)
AU (1) AU2008313405B2 (de)
BR (1) BRPI0816536A2 (de)
CA (1) CA2701953C (de)
CL (1) CL2008003083A1 (de)
CO (1) CO6270209A2 (de)
CY (1) CY1112604T1 (de)
DE (1) DE08838691T1 (de)
DK (2) DK2187878T3 (de)
ES (2) ES2368299T3 (de)
HK (1) HK1148940A1 (de)
HR (2) HRP20110659T1 (de)
IL (1) IL205129A (de)
MA (1) MA31843B1 (de)
MX (1) MX2010004295A (de)
MY (1) MY156750A (de)
NZ (1) NZ584307A (de)
PA (1) PA8799401A1 (de)
PL (2) PL2187878T3 (de)
PT (2) PT2233135E (de)
RU (1) RU2471500C2 (de)
SI (2) SI2233135T1 (de)
TN (1) TN2010000170A1 (de)
TW (1) TWI531365B (de)
WO (1) WO2009050567A2 (de)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2050441A1 (de) 2007-10-19 2009-04-22 Université Victor Segalen Bordeaux 2 Verwendung von Beta-Blockern für die Herstellung eines Medikaments zur Behandlung von Hämangiomen
US8987262B2 (en) 2007-10-19 2015-03-24 Universite de Bordeaux Use of a beta blocker for the manufacture of a medicament for the treatment of hemangiomas
WO2010118340A1 (en) 2009-04-09 2010-10-14 University Of Medicine And Dentistry Of New Jersey Treatment of cutaneous hemangioma
EP2246044A1 (de) 2009-04-21 2010-11-03 Pierre Fabre Dermo-Cosmétique Kinderärztliche Lösungen für Betablocker
US20140170112A1 (en) * 2011-03-12 2014-06-19 Vicus Therapeutics, Llc Compositions for ameliorating systemic inflammation and methods for making and using them
CN102579412A (zh) * 2012-02-16 2012-07-18 山东省立医院 一种治疗婴幼儿血管瘤的外用药物及其制备方法
CN103536607A (zh) * 2012-07-10 2014-01-29 邵金辉 土霉素，普罗帕酮和安乃近的抗肿瘤作用
CN103054793B (zh) * 2013-01-05 2015-01-21 广州军区广州总医院 一种用于治疗婴幼儿血管瘤的盐酸普萘洛尔乳膏及其制备方法
WO2014150899A1 (en) * 2013-03-15 2014-09-25 Chapin Matthew J Topical ophthalmic formulations for treating migraine
CN104274390B (zh) * 2014-09-04 2017-06-13 郑家伟 一种噻吗洛尔长效透皮制剂及其在血管瘤中的应用
RU2584082C1 (ru) * 2015-01-21 2016-05-20 Ильдар Наилевич Нурмеев Способ лечения гемангиом
CN105434337B (zh) * 2015-04-03 2019-08-16 武汉科福新药有限责任公司 盐酸普萘洛尔亚微乳凝胶及其制备方法和用途
CN105106105A (zh) * 2015-08-14 2015-12-02 天津市聚星康华医药科技有限公司 噻吗洛尔外用制剂治疗婴幼儿血管瘤的应用及其制备方法
US20170360829A1 (en) * 2016-01-27 2017-12-21 Gillies Mcindoe Research Institute Treatment of vascular anomalies
RU2617516C1 (ru) * 2016-03-24 2017-04-25 Государственное бюджетное учреждение здравоохранения города Москвы Научно-исследовательский институт неотложной детской хирургии и травматологии Департамента здравоохранения города Москвы Способ лечения младенческих гемангиом
CN106474061B (zh) * 2016-12-08 2019-01-22 黑龙江童医生儿童生物制药有限公司 一种盐酸普萘洛尔口服乳剂及其制备方法
CN108261411B (zh) * 2016-12-30 2021-04-30 武汉科福新药有限责任公司 用于婴幼儿血管瘤治疗的口腔膜剂及其制备方法
EA202090452A1 (ru) * 2017-08-07 2020-06-15 Консехо Супериор Де Инвестигасионес Сьентификас Соединения для лечения болезни фон гиппеля-линдау
US20190133974A1 (en) 2017-11-07 2019-05-09 University Of South Florida Methods for detecting and treating propranolol sensitive tumors
CN108299279B (zh) * 2018-02-09 2021-03-23 北京梅尔森医药技术开发有限公司 取代芳基胺醇化合物及其制备方法和用途
CN110314154A (zh) * 2018-03-28 2019-10-11 武汉恒信源药业有限公司 左旋普萘洛尔在制备治疗血管病变药物中的应用
US20210346319A1 (en) * 2018-10-04 2021-11-11 Emory University Pharmaceutical Compositions of R-(+)-Propranolol in Enantiomeric Excess and Therapeutic Uses Related Thereto
RU2701213C1 (ru) * 2018-12-27 2019-09-25 Федеральное государственное бюджетное образовательное учреждение высшего образования "Российский национальный исследовательский медицинский университет имени Н.И. Пирогова" Министерства здравоохранения Российской Федерации (ФГБОУ ВО РНИМУ им. Н.И. Пирогова Минздрава России) Способ лечения инфантильных гемангиом
US11154518B2 (en) * 2018-12-28 2021-10-26 Chang Gung Memorial Hospital, Linkou Methods and apparatus for treating a wound
EP3976008A4 (de) * 2019-05-24 2023-07-05 Pediatric Derm Developement LLC Behandlung von infantilen hämangiomen
CN111773226A (zh) * 2019-06-26 2020-10-16 首都医科大学附属北京儿童医院 噻吗洛尔或其盐在制备预防和/或治疗丛状血管瘤的药物中的用途
AU2021212568B2 (en) * 2020-01-29 2024-12-12 Gillies Mcindoe Research Institute Methods and compositions for the treatment of hemangioma
WO2022007878A1 (zh) * 2020-07-10 2022-01-13 长庚医疗财团法人林口长庚纪念医院 β-1肾上腺素受体拮抗剂用于制备减少表皮生长因子受体抑制剂诱导的上皮细胞损伤以及抑制癌细胞的组合物的用途
TW202228662A (zh) 2020-09-30 2022-08-01 日商日產化學股份有限公司 含有水溶性β阻斷劑及卵磷脂之複合體
CN113274348A (zh) * 2021-06-11 2021-08-20 四川大学华西医院 用于治疗婴幼儿血管瘤的阿替洛尔凝胶、制备方法及应用
PL244294B1 (pl) * 2022-09-20 2024-01-03 Univ Medyczny W Lodzi Kompozycja farmaceutyczna do stosowania miejscowego oraz jej zastosowanie w leczeniu naczyniaków krwionośnych u dzieci
US12257255B1 (en) 2024-01-23 2025-03-25 Auson Pharmaceuticals Inc. Timolol maleate gel for topical administration

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL301580A (de) 1962-12-11
US3466325A (en) 1965-04-30 1969-09-09 Haessle Ab 1-(ortho-alkenyl phenoxy) - 2-hydroxy-3-isopropylaminopropanes and the salts thereof
US3657237A (en) 1968-05-22 1972-04-18 Frosst & Co Charles E Process for making 1 2 5-thiadiazoles in the sinister configuration
GB1253709A (en) 1968-05-22 1971-11-17 Frosst & Co Charles E Thiadiazole derivatives
US3655663A (en) 1969-04-21 1972-04-11 Burton K Wasson 4-(3-secondary amino-2-hydroxy-proxy) 1 2 5-thiadiazoles
SE354851B (de) 1970-02-18 1973-03-26 Haessle Ab
AT334385B (de) 1973-12-20 1976-01-10 Chemie Linz Ag Verfahren zur herstellung von neuen phenoxypropylaminderivaten und deren salzen
FR2330383A1 (fr) 1975-11-06 1977-06-03 Synthelabo Nouveaux ethers de phenols substitues, leurs sels, leur preparation et les medicaments qui les renferment
US5116867A (en) * 1989-06-30 1992-05-26 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services D-propranolol as a selective adenosine antagonist
US5182102A (en) * 1991-07-12 1993-01-26 Alcon Laboratories, Inc. Anti-glaucoma compositions
CN101007173A (zh) * 1993-07-19 2007-08-01 血管技术药物公司 抗血管生长组合物及使用方法
US6232299B1 (en) * 1996-05-01 2001-05-15 Eli Lilly And Company Use of protein kinase C inhibitors to enhance the clinical efficacy of oncolytic agents and radiation therapy
BR9710706A (pt) * 1996-05-01 1999-08-17 Lilly Co Eli Tratamento terap-utico para doen-as relacionadas a vegf
GB9616672D0 (en) * 1996-08-08 1996-09-25 Scherer Ltd R P Pharmaceutical compositions
JP2004528378A (ja) 2001-05-08 2004-09-16 シエーリング アクチエンゲゼルシャフト Ｎ−オキシドアントラニルアミド誘導体と医薬製剤としての利用
US20050244458A1 (en) * 2004-04-30 2005-11-03 Allergan, Inc. Sustained release intraocular implants and methods for treating ocular neuropathies
WO2006015830A1 (en) * 2004-08-09 2006-02-16 Universite Catholique De Louvain Use of agonists and antagonists of beta-adrenoceptors for treating arterial diseases
TW200716141A (en) * 2005-05-05 2007-05-01 Combinatorx Inc Compositions and methods for treatment for neoplasms
EP2050441A1 (de) 2007-10-19 2009-04-22 Université Victor Segalen Bordeaux 2 Verwendung von Beta-Blockern für die Herstellung eines Medikaments zur Behandlung von Hämangiomen
US8987262B2 (en) 2007-10-19 2015-03-24 Universite de Bordeaux Use of a beta blocker for the manufacture of a medicament for the treatment of hemangiomas

Also Published As

Publication number Publication date
EP2233135B1 (de) 2012-06-27
CN102006864A (zh) 2011-04-06
DK2233135T3 (da) 2012-10-01
EP2187878A2 (de) 2010-05-26
EP2187878B1 (de) 2011-06-15
CL2008003083A1 (es) 2009-03-06
IL205129A0 (en) 2010-11-30
US9173858B2 (en) 2015-11-03
PL2187878T3 (pl) 2012-01-31
HRP20120765T1 (hr) 2012-10-31
RU2471500C2 (ru) 2013-01-10
US20130072551A1 (en) 2013-03-21
KR20150110827A (ko) 2015-10-02
US8338489B2 (en) 2012-12-25
EP2233135A1 (de) 2010-09-29
US20100273889A1 (en) 2010-10-28
CY1112604T1 (el) 2016-02-10
NZ584307A (en) 2012-03-30
IL205129A (en) 2015-05-31
TN2010000170A1 (en) 2011-11-11
JP5552700B2 (ja) 2014-07-16
CN102006864B (zh) 2013-01-16
PT2233135E (pt) 2012-09-06
SI2187878T1 (sl) 2011-10-28
HK1148940A1 (en) 2011-09-23
EP2050441A1 (de) 2009-04-22
PL2233135T3 (pl) 2012-11-30
AU2008313405B2 (en) 2013-12-19
CO6270209A2 (es) 2011-04-20
SI2233135T1 (sl) 2012-10-30
WO2009050567A2 (en) 2009-04-23
WO2009050567A3 (en) 2009-06-18
PA8799401A1 (es) 2009-05-15
PT2187878E (pt) 2011-09-07
ES2368299T3 (es) 2011-11-16
KR101562627B1 (ko) 2015-10-22
MX2010004295A (es) 2010-08-02
AR068927A1 (es) 2009-12-16
RU2010112816A (ru) 2011-11-27
DE08838691T1 (de) 2010-08-26
MY156750A (en) 2016-03-31
JP2011500661A (ja) 2011-01-06
BRPI0816536A2 (pt) 2017-06-06
KR20100087012A (ko) 2010-08-02
AU2008313405A1 (en) 2009-04-23
CN103169971A (zh) 2013-06-26
HRP20110659T1 (hr) 2011-10-31
CA2701953C (en) 2015-05-19
CA2701953A1 (en) 2009-04-23
TW200932207A (en) 2009-08-01
EP2233135B8 (de) 2013-07-10
MA31843B1 (fr) 2010-11-01
DK2187878T3 (da) 2011-09-19
TWI531365B (zh) 2016-05-01
ES2390534T3 (es) 2012-11-13

Similar Documents

Publication Publication Date Title
ATE512661T1 (de) Verwendung eines betablockers zur herstellung eines arzneimittels zur behandlung von hämangiomen
GB2453188B (en) Use of compounds in the manufacture of medicaments for treatment of regional fat deposits
ZA201003110B (en) Novel cyclic hydrocarbon compounds for the treatment of diseases
EP2620169A4 (de) Blutaufbereitungsfilter und verfahren zur herstellung des blutaufbereitungsfilters
EP2362777A4 (de) Verwendung von pharmazeutischen zusammensetzungen bei der herstellung von arzneimitteln zur behandlung von diabetischem geschwür
EP2165684A4 (de) Stent, mikrokatheter, durchgehende schlauchartige elementumhüllungsvorrichtung und verfahren zur herstellung des stents
EP2797942A4 (de) Zusammensetzung aus neuartigem kohlenhydratarzneimittel zur behandlung von menschenkrankheiten
IL216967A0 (en) 17-hydroxy-17-pentafluorethyl-estra-4,9(10)-dien-11-aryl derivatives, method of production thereof and use thereof for the treatment of diseases
EP3821910C0 (de) Oligosaccharid und verfahren zur herstellung davon
ATE477798T1 (de) Verwendung von agomelatin zur herstellung von medikamenten zur behandlung der generalisierten angststörung
DE502008000313D1 (de) Verfahren zur kontinuierlichen Herstellung von Aminoalkylgruppen aufweisenden Organopolysiloxanen
EP2364711A4 (de) Verwendung von extrakten aus vaccinia-virus-entzündetem kaninchenfell zur herstellung eines medikaments zur behandlung akuter hirngefässerkrankungen
ATE510536T1 (de) Verwendung von 2,5-dihydroxybenzol-derivaten zur behandlung von reaktiven gewebeerkrankungen
DE502008000497D1 (de) Verfahren zur Herstellung eines Tuftprodukts, Tuftprodukt und dessen Verwendung
ATE381929T1 (de) Verwendung von resveratrol zur herstellung eines arzneimittels zur behandlung von grippe
EP2195036A4 (de) Zusammensetzungen zur behandlung von tumoren durch direkte verabreichung eines radioisotops
GB0724226D0 (en) Composition for the treatment of a detached retina and method of production thereof
ATE491443T1 (de) Verwendung des agomelatins zur herstellung eines medikamentes zur behandlung der bipolaren erkrankungen
ATE520393T1 (de) Verwendung von cb1-rezeptor-antagonisten zur herstellung eines arzneimittels zur behandlung von lebererkrankungen
ATE481393T1 (de) Neue cycloalkyl-benzothiadiazin-derivate, ihr herstellungsverfahren und die pharmazeutischen zusammensetzungen, die sie enthalten
DE602008001384D1 (de) Maschine zur Herstellung und/oder Verpackung von Tabakerzeugnissen
ATE527997T1 (de) Verwendung von aminapthon zur herstellung eines medikaments zur behandlung von arteriopathien
PL2307380T3 (pl) Pochodne N’-nitroksyalkilonikotynamidu do leczenia chorób układu sercowo-naczyniowego
DE602005000442D1 (de) Verwendung von alpha-1-Antitrypsin zur Herstellung eines Medikaments zur Behandlung von Fibromyalgie
DE112009003270A5 (de) Filtereinsatz und verfahren zur herstellung des filtereinsatzes

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 2187878

Country of ref document: EP